Biophytis SA, a leading clinical-stage biotechnology company focused on developing therapeutics for age-related diseases, has recently filed Form 25-NSE with the Securities and Exchange Commission (SEC). This form is used to notify the SEC of the removal of a security from listing and registration on a national securities exchange. The significance of this filing suggests that Biophytis SA may be delisting or deregistering its securities from a national securities exchange, which could have implications for its shareholders and investors.
Biophytis SA, traded under the ticker symbol “BPTS” on the Nasdaq Stock Exchange, is known for its innovative approach to targeting the molecular pathways involved in the aging process. The company’s pipeline includes promising drug candidates for neuromuscular and age-related diseases such as sarcopenia and diabetic retinopathy. For more information about Biophytis SA and its groundbreaking research and development efforts, please visit their website at https://www.biophytis.com/.
Overall, the submission of Form 25-NSE by Biophytis SA indicates a significant corporate action that may impact its trading activity and regulatory obligations. Investors and stakeholders should stay informed about the company’s future plans and strategic decisions as it continues to advance its mission of addressing unmet medical needs associated with aging through innovative biopharmaceutical solutions.
Read More:
Biophytis SA Submits Form 25-NSE to the SEC – Find Out More About the Filing
